InMed Shares Research in Peer-Reviewed Publication

- March 6th, 2018

InMed Pharmaceuticals shared the publication of a peer-reviewed article Drug Delivery and Translational Research showing pre-clinical study results from research co-sponsored by InMed.

InMed Pharmaceuticals (CSE:IN; OTCQB:IMLFF) shared the publication of a peer-reviewed article Drug Delivery and Translational Research showing pre-clinical study results from research co-sponsored by InMed.

As quoted in the press release:

The article, titled “A stimulus-responsive, in situ forming, nanoparticle-laden hydrogel for ocular drug delivery”, presents results from a pre-clinical study co-sponsored by InMed and was co-authored by Dr. Sazzad Hossain, InMed’s Chief Scientific Officer.

In October, 2017, InMed originally announced completion of this study.  These proprietary data support what the Company believes to be a first-in-class nanoparticle-hydrogel formulation for cannabinoid delivery to the eye, resulting in enhanced drug uptake via the cornea and lens.  The patent family for this discovery is currently at the provisional stage and will be converted to a PCT filing during 2018.

Click here to read the full press release.

Get the latest Cannabis Investing stock information

Get the latest information about companies associated with Cannabis Investing Delivered directly to your inbox.

Cannabis Investing

Select All
Select None

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time

Leave a Reply

Your email address will not be published. Required fields are marked *